{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:28:20Z","timestamp":1793698100434,"version":"4.5.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404680"],"award-info":[{"award-number":["82404680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","award":["Y202457110"],"award-info":[{"award-number":["Y202457110"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY1445"],"award-info":[{"award-number":["2024KY1445"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008043","name":"Zhejiang Sci-Tech University","doi-asserted-by":"publisher","award":["26042173-Y"],"award-info":[{"award-number":["26042173-Y"]}],"id":[{"id":"10.13039\/501100008043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjms.2026.08.023","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:54:30Z","timestamp":1787727270000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond monotherapy: The evolving role of CTLA-4 in combination immunotherapy for gastrointestinal cancers"],"prefix":"10.1016","author":[{"given":"Fuyuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.amjms.2026.08.023_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.canlet.2021.09.034","article-title":"Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America","volume":"522","author":"Li","year":"2021","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.amjms.2026.08.023_bib0003","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.18632\/oncotarget.6770","article-title":"The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.amjms.2026.08.023_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ctrv.2017.08.007","article-title":"Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies","volume":"60","author":"Chiaravalli","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.amjms.2026.08.023_bib0005","article-title":"Construction of a new clinical staging system for colorectal cancer based on the lymph node ratio: a validation study","volume":"9","author":"Yang","year":"2022","journal-title":"Front Surg"},{"issue":"11","key":"10.1016\/j.amjms.2026.08.023_bib0006","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.4251\/wjgo.v13.i11.1668","article-title":"Novel perspective in pancreatic cancer therapy: targeting ferroptosis pathway","volume":"13","author":"Yang","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.amjms.2026.08.023_bib0007","article-title":"Biomarkers in immunotherapy-based precision treatments of digestive system tumors","volume":"11","author":"Zeng","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.023_bib0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13543784.2019.1559297","article-title":"CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy","volume":"28","author":"Szostak","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.amjms.2026.08.023_bib0009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jvh.13055","article-title":"Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B","volume":"26","author":"Zhou","year":"2019","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.amjms.2026.08.023_bib0010","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1007\/s00330-018-5814-3","article-title":"Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect","volume":"29","author":"Du","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.amjms.2026.08.023_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0012","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.023_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5114\/ada.2019.84590","article-title":"Molecular background of skin melanoma development and progression: therapeutic implications","volume":"36","author":"Olbryt","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/s12967-023-04422-x","article-title":"Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors","volume":"21","author":"Yang","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.amjms.2026.08.023_bib0016","first-page":"33","article-title":"Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment","volume":"7","author":"Tang","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.amjms.2026.08.023_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1602452","article-title":"Role of tgf\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy","volume":"15","author":"Hou","year":"2025","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.amjms.2026.08.023_bib0019","article-title":"Oncolytic viruses and pancreatic cancer","volume":"31","author":"Hamidi-Sofiani","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0020","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cbin.11559","article-title":"A recombinant influenza virus with a CTLA4-specific scFv inhibits tumor growth in a mouse model","volume":"45","author":"Lei","year":"2021","journal-title":"Cell Biol Int"},{"issue":"9","key":"10.1016\/j.amjms.2026.08.023_bib0021","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-20-4632","article-title":"A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer","volume":"27","author":"Monjazeb","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.023_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188447","article-title":"Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside","volume":"1874","author":"Lizardo","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"23","key":"10.1016\/j.amjms.2026.08.023_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314672","article-title":"DNA damage response in cancer therapy and resistance: challenges and opportunities","volume":"23","author":"Jurkovicova","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0024","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjms.2026.08.023_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.774330","article-title":"Characterization of esophageal microbiota in patients with esophagitis and esophageal squamous cell carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"18","key":"10.1016\/j.amjms.2026.08.023_bib0026","doi-asserted-by":"crossref","first-page":"26670","DOI":"10.18632\/oncotarget.8476","article-title":"Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.amjms.2026.08.023_bib0027","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/cco.2017.09.03","article-title":"Systemic therapy for esophagogastric cancer: immune checkpoint inhibition","volume":"6","author":"Lyons","year":"2017","journal-title":"Chin Clin Oncol"},{"issue":"19","key":"10.1016\/j.amjms.2026.08.023_bib0028","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of sequential Ipilimumab monotherapy versus best supportive care for unresectable locally advanced\/metastatic gastric or gastroesophageal junction cancer","volume":"23","author":"Bang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.amjms.2026.08.023_bib0029","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41392-022-01022-x","article-title":"Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.amjms.2026.08.023_bib0031","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amjms.2026.08.023_bib0032","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14737140.2019.1654379","article-title":"Immune checkpoint inhibitors: a new era for esophageal cancer","volume":"19","author":"Zou","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.amjms.2026.08.023_bib0033","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cac2.12645","article-title":"Current status and perspectives of esophageal cancer: a comprehensive review","volume":"45","author":"Jiang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12935-025-03655-8","article-title":"A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies","volume":"25","author":"Panahizadeh","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.amjms.2026.08.023_bib0035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/1078-0432.CCR-19-2443","article-title":"Safety and efficacy of Durvalumab and Tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma","volume":"26","author":"Kelly","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.amjms.2026.08.023_bib0036","doi-asserted-by":"crossref","first-page":"760","DOI":"10.4143\/crt.2024.718","article-title":"Association of pro-inflammatory cytokines with gastric cancer risk: a case-cohort study","volume":"57","author":"Baek","year":"2025","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0037","article-title":"LZTS2 methylation as a potential diagnostic and prognostic marker in LIHC and STAD: evidence from bioinformatics and in vitro analyses","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.amjms.2026.08.023_bib0038","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5254","article-title":"Advances in immune therapies for the treatment of microsatellite instability-high\/deficient mismatch repair metastatic colorectal cancer (Review)","volume":"59","author":"Choucair","year":"2021","journal-title":"Int J Oncol"},{"issue":"12","key":"10.1016\/j.amjms.2026.08.023_bib0039","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.3390\/ijms25126730","article-title":"The role of the PAX genes in renal cell carcinoma","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.amjms.2026.08.023_bib0040","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jjco\/hyad195","article-title":"First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study","volume":"54","author":"Imai","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0041","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/mco.2024.2788","article-title":"Inflammation-based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: tokushukai REAl-world Data project 02 (TREAD 02)","volume":"21","author":"Shimoyama","year":"2024","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"10.1016\/j.amjms.2026.08.023_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114088","article-title":"IFN\u03b1-induced BST2(+) tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling","volume":"43","author":"Zheng","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.amjms.2026.08.023_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1498391","article-title":"c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity","volume":"15","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0044","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2008.03.056","article-title":"Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer","volume":"268","author":"Loos","year":"2008","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/jso.26359","article-title":"Pancreas cancer: therapeutic trials in metastatic disease","volume":"123","author":"Smithy","year":"2021","journal-title":"J Surg Oncol"},{"issue":"8","key":"10.1016\/j.amjms.2026.08.023_bib0046","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.amjms.2026.08.023_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117430","article-title":"Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer","volume":"179","author":"Ni","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0048","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"10.1016\/j.amjms.2026.08.023_bib0049","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3748\/wjg.v24.i20.2137","article-title":"Immune therapies in pancreatic ductal adenocarcinoma: where are we now?","volume":"24","author":"Hilmi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjms.2026.08.023_bib0050","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3389\/fimmu.2017.01476","article-title":"Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer","volume":"8","author":"Muraro","year":"2017","journal-title":"Front Immunol"},{"issue":"27","key":"10.1016\/j.amjms.2026.08.023_bib0051","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.amjms.2026.08.023_bib0052","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3748\/wjg.v28.i7.745","article-title":"Stereotactic radiotherapy and the potential role of magnetic resonance-guided adaptive techniques for pancreatic cancer","volume":"28","author":"Ermongkonchai","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0053","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.hbpd.2023.03.002","article-title":"Stereotactic body radiotherapy in pancreatic adenocarcinoma","volume":"23","author":"De La Pinta","year":"2024","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0054","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.amjms.2026.08.023_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044654","article-title":"A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression","volume":"7","author":"Simone","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2026.08.023_bib0056","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.omto.2021.01.010","article-title":"Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment","volume":"20","author":"Tan","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.023_bib0057","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae220","article-title":"Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study","volume":"30","author":"Monteiro","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0058","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mc.23401","article-title":"The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-\u03b2 receptor plus dual checkpoint inhibition maintains antitumor immune cells","volume":"61","author":"Rana","year":"2022","journal-title":"Mol Carcinog"},{"issue":"7","key":"10.1016\/j.amjms.2026.08.023_bib0059","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjms.2026.08.023_bib0060","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820948773","article-title":"Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers","volume":"13","author":"Eso","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"issue":"10","key":"10.1016\/j.amjms.2026.08.023_bib0061","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.amjms.2026.08.023_bib0062","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/genes16060667","article-title":"Advances in genitourinary tumor genomics and immunotherapy","volume":"16","author":"Vohra","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.amjms.2026.08.023_bib0063","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.2147\/IJN.S388075","article-title":"Nanoparticles for chemoimmunotherapy against triple-negative breast cancer","volume":"17","author":"Liu","year":"2022","journal-title":"Int J Nanomedicine"},{"issue":"8","key":"10.1016\/j.amjms.2026.08.023_bib0064","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.023_bib0065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3892\/ol.2024.14846","article-title":"Application of CellSearch technique in detection of peripheral blood circulating tumour cell count in patients with head and neck cancer and its association with prognosis","volume":"29","author":"Li","year":"2025","journal-title":"Oncol Lett"},{"key":"10.1016\/j.amjms.2026.08.023_bib0066","article-title":"The emerging role of tissue-resident memory CD8(+) T lymphocytes in Human digestive tract cancers","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.amjms.2026.08.023_bib0067","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/cancers15164156","article-title":"Tumor endothelial cells-associated Integrin alpha-6 as a promising biomarker for early detection and prognosis of hepatocellular carcinoma","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjms.2026.08.023_bib0068","article-title":"Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: current status, possible mechanisms and application prospects","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.amjms.2026.08.023_bib0069","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","article-title":"Tyrosine kinase signaling-independent MET-targeting with CAR-T cells","volume":"21","author":"Qin","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.amjms.2026.08.023_bib0071","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41571-023-00733-6","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.amjms.2026.08.023_bib0072","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251339243","article-title":"Prognostic biomarkers for hepatocellular carcinoma patients treated with Atezolizumab plus Bevacizumab combination Therapy","volume":"32","author":"Jeng","year":"2025","journal-title":"Cancer Control"},{"issue":"7","key":"10.1016\/j.amjms.2026.08.023_bib0073","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.3390\/ijms25074117","article-title":"Tumor and peritoneum-associated macrophage gene signature as a novel molecular biomarker in gastric cancer","volume":"25","author":"Sullivan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.023_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000166","article-title":"Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I\/II study","volume":"8","author":"Verdegaal","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.amjms.2026.08.023_bib0075","first-page":"167","article-title":"Immunotherapy in gastrointestinal cancers: current insights","volume":"17","author":"Jiang","year":"2025","journal-title":"Clin Pharmacol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:02:48Z","timestamp":1793696568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962926003551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":75,"alternative-id":["S0002962926003551"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2026.08.023","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond monotherapy: The evolving role of CTLA-4 in combination immunotherapy for gastrointestinal cancers","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2026.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}